Latest News

26.07.2021.

Awakn announces U.S. trading on OTC market under AWKNF

READ MORE

22.07.2021.

Prof Barbara Mason Joins Awakns Clinical Advisory Board

READ MORE

14.07.2021.

Awakn Initiates Ketamine Research Programs For Addiction Treatment

READ MORE

07.07.2021.

Awakn Establishes Preclinical And Clinical Expert Advisory Boards

READ MORE

28.06.2021.

Awakn Files Patent Applications For 2 New Chemical Entities To Treat Addiction

READ MORE

24.06.2021.

Awakn Appoints Prof. David Nutt As its Chief Research Officer

READ MORE

23.06.2021.

Awakn Commences Trading on the NEO Exchange under the Symbol ‘AWKN’

READ MORE

See News Archive »

Sign Up for Newsletter:

MAIN OFFICE
Suite 200, 366 Bay St,
Toronto, Ontario, M5H 4B2, Canada

UK OFFICE
1 Regent Street,
Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy